R&D News_R&D News_R&D

Z6·尊龙凯时「中国」官方网站Z6·尊龙凯时「中国」官方网站

R&D News

2021-10-28
Nature Dialogue with Dr. Aimin Hui: How to Lead R&D of Innovator Drugs?

Chinese pharmaceutical companies are turning their attention to innovation, shifting rapidly from mastery of follow-on drugs to researching first-in-class and best-in-class drugs. Aiming to be a healthcare group with a global presence, Fosun Pharma, established in Shanghai in 1994, has built its core business around innovative drug R&D and manufacturing.

More
2021-10-07
Innovation for Health — The Fourth Hongqiao International Health Technology Innovation Forum Held in Shanghai

On November 6, 2021, as a parallel supporting event of the 4th China International Import Expo (CIIE), the 4th Hongqiao International Health Technology Innovation Forum with the theme of "Innovation for Good Health" was successfully held. This forum was sponsored by the International Health Exchange and Cooperation Center NHC PRC (IHECC) and China Pharmaceutical Innovation and Research Development Association,

More
2021-09-28
2021 CSCO | Henlius Publishes Newest Phase II Clinical Data of Novel Anti-PD-1 mAb Serplulimab for Treatment of Advanced Cervical Cancer

In this meeting, Henlius releases phase 2 study results of serplulimab (HLX10, novel anti-PD-1 antibody), in patients with advanced cervical cancer in an oral presentation.

More
2021-09-28
2021 CSCO | Henlius Publishes Phase III Clinical Data of Bevacizumab Biosesimilar HLX04 for Treatment of Metastatic Colorectal Cancer

In this meeting, Henlius releases phase 3 study results of HLX04 (bevacizumab biosesimilar), in patients with metastatic colorectal cancer in an oral presentation.

More

Total：38 Home Previous Page 1 2 3 4 5 Next Page Last The Number Of Pages：5/5 GO

Z6·尊龙凯时「中国」官方网站

Z6·尊龙凯时「中国」官方网站Z6·尊龙凯时「中国」官方网站

Our Company

Our Business

R&D

Sustainability

Investor Relations

News

Careers

R&D News

Nature Dialogue with Dr. Aimin Hui: How to Lead R&D of Innovator Drugs?

Innovation for Health — The Fourth Hongqiao International Health Technology Innovation Forum Held in Shanghai

2021 CSCO | Henlius Publishes Newest Phase II Clinical Data of Novel Anti-PD-1 mAb Serplulimab for Treatment of Advanced Cervical Cancer

2021 CSCO | Henlius Publishes Phase III Clinical Data of Bevacizumab Biosesimilar HLX04 for Treatment of Metastatic Colorectal Cancer

Brief Product News | New Progress in Henlius Anti-HER2 Therapy! First Patient Dosed in Phase 1 Clinical Trial of Henlius Pertuzumab Biosesimilar HLX11

Henlius Bevacizumab Biosesimilar HLX04 Receives NDA Acceptance Notification from NMPA